Get the Stockscreener App
0.2886
6.53%
0.0177
After Hours:
.30
0.0114
+3.95%
Ovid Therapeutics Inc stock is traded at $0.2886, with a volume of 222.82K.
It is up +6.53% in the last 24 hours and down -38.08% over the past month.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential in-class mechanism of action.
See More
Previous Close:
$0.2709
Open:
$0.282
24h Volume:
222.82K
Relative Volume:
0.57
Market Cap:
$20.40M
Revenue:
$391.70K
Net Income/Loss:
$-52.34M
P/E Ratio:
-0.3848
EPS:
-0.75
Net Cash Flow:
$-45.92M
1W Performance:
+13.18%
1M Performance:
-38.08%
6M Performance:
-75.33%
1Y Performance:
-90.72%
1-Day Range:
$0.272
$0.2912
1-Week Range:
$0.255
$0.3029
52-Week Range:
$0.2425
$3.45
Ovid Therapeutics Inc Stock (OVID) Company Profile
Name
Ovid Therapeutics Inc
Sector
Industry
Phone
212-776-4381
Address
441 NINTH AVENUE, 14TH FLOOR, NEW YORK, NY
Compare OVID with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OVID
Ovid Therapeutics Inc
|
0.2886 | 20.40M | 391.70K | -52.34M | -45.92M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Ovid Therapeutics Inc Stock (OVID) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-18-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Apr-30-24 | Initiated | B. Riley Securities | Buy |
| Apr-29-24 | Initiated | H.C. Wainwright | Buy |
| Apr-05-24 | Initiated | Wedbush | Outperform |
| Dec-21-23 | Initiated | BTIG Research | Buy |
| Oct-13-23 | Initiated | Oppenheimer | Outperform |
| Apr-20-21 | Downgrade | Cantor Fitzgerald | Buy → Neutral |
| Mar-03-21 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Dec-02-20 | Downgrade | Citigroup | Buy → Neutral |
| Dec-02-20 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Sep-04-19 | Initiated | RBC Capital Mkts | Outperform |
| Apr-20-18 | Initiated | Ladenburg Thalmann | Buy |
View All
Ovid Therapeutics Inc Stock (OVID) Latest News
Dravet Syndrome Treatment Market Future Business - openPR.com
Ovid Therapeutics stock hits 52-week low at $0.27 By Investing.com - Investing.com South Africa
Ovid Therapeutics stock hits 52-week low at $0.27 - Investing.com
Ovid Therapeutics Advances Pipeline Amid Financial Progress - TipRanks
Ovid Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference - GlobeNewswire
Key Brain Medicine Updates: Ovid Therapeutics Takes Center Stage at Major Healthcare Conference - Stock Titan
Ovid Therapeutics Inc. (NASDAQ:OVID) Receives $3.03 Consensus Target Price from Brokerages - Defense World
Ovid Therapeutics stock hits 52-week low at $0.35 amid downturn By Investing.com - Investing.com South Africa
Ovid Therapeutics stock hits 52-week low at $0.35 amid downturn - Investing.com Canada
HC Wainwright Lifts Earnings Estimates for Ovid Therapeutics - Defense World
FY2026 Earnings Forecast for OVID Issued By HC Wainwright - Defense World
Ovid Therapeutics (NASDAQ:OVID) Price Target Lowered to $4.00 at BTIG Research - Defense World
Ovid Therapeutics stock target cut to $2 at H.C. Wainwright By Investing.com - Investing.com Australia
Ovid Therapeutics stock target cut to $2 at H.C. Wainwright - Investing.com
BTIG cuts Ovid Therapeutics stock price target to $4 By Investing.com - Investing.com South Africa
BTIG cuts Ovid Therapeutics stock price target to $4 - Investing.com
Ovid Therapeutics stock hits 52-week low at $0.42 amid market challenges - Investing.com
Ovid Therapeutics stock hits 52-week low at $0.42 amid market challenges By Investing.com - Investing.com South Africa
West syndrome Pipeline 2025: Mechanism of Action, Route - openPR
Q1 EPS Forecast for Ovid Therapeutics Raised by Analyst - Defense World
What is Wedbush’s Estimate for OVID FY2029 Earnings? - Defense World
William Blair Forecasts Lower Earnings for Ovid Therapeutics - Defense World
What is William Blair’s Estimate for OVID Q1 Earnings? - Defense World
Wedbush Adjusts Price Target on Ovid Therapeutics to $3 From $4, Keeps Outperform Rating - MarketScreener
Ovid Therapeutics earnings beat by $0.04, revenue fell short of estimates - Investing.com Canada
Ovid Therapeutics’ Cybersecurity Challenges: Navigating IT Risks and Third-Party Dependencies - TipRanks
Ovid Therapeutics stock plunges to 52-week low of $0.46 - Investing.com India
Ovid Therapeutics stock plunges to 52-week low of $0.46 By Investing.com - Investing.com South Africa
Ovid Therapeutics (OVID) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
Ovid Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Ovid Therapeutics Reports Business Updates and Fourth Quarter and Full Year 2024 Financial Results - The Manila Times
Ovid Therapeutics Secures 2-Year Cash Runway as 3 Novel Drug Programs Progress - StockTitan
We're A Little Worried About Ovid Therapeutics' (NASDAQ:OVID) Cash Burn Rate - Yahoo Finance
Ovid Therapeutics (OVID) Expected to Announce Earnings on Friday - Defense World
Trump's FDA chief pick Makary to face overhauling agency, keeping Kennedy happy -March 06, 2025 at 06:00 am EST - Marketscreener.com
Ovid Therapeutics Inc. (NASDAQ:OVID) Receives $4.03 Consensus Target Price from Brokerages - Defense World
Ovid Therapeutics appoints new board member and updates compensation policy - Investing.com India
Ovid Therapeutics appoints new board member and updates compensation policy By Investing.com - Investing.com South Africa
Ovid Therapeutics Expands Board with New Appointment - TipRanks
Ovid Therapeutics Inc expected to post a loss of 17 cents a shareEarnings Preview - TradingView
Ovid Therapeutics Appoints Dr. Stelios Papadopoulos To Board - citybiz
Ovid Therapeutics Appoints Pioneering Industry Leader Dr. Stelios Papadopoulos to Board of Directors - GlobeNewswire
Ovid therapeutics CBFO sells $2,185 in stock - Investing.com India
Ovid therapeutics CBFO sells $2,185 in stock By Investing.com - Investing.com Australia
Ovid therapeutics president and COO sells $2,956 in stock By Investing.com - Investing.com Canada
Ovid Therapeutics Inc Stock (OVID) Financials Data
Revenue
Net Income
Cash Flow
EPS
Ovid Therapeutics Inc Stock (OVID) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Rona Jeffrey A | CBFO |
Feb 26 '25 |
Sale |
0.56 |
3,902 |
2,185 |
67,973 |
| ALEXANDER MARGARET A. | President and COO |
Jan 27 '25 |
Buy |
0.73 |
6,810 |
4,971 |
34,935 |
2.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):